Pharvaris reported Phase 3 topline success for deucrictibant as an on‑demand oral treatment for hereditary angioedema (HAE), with a median time to symptom relief of 1.28 hours and median time to complete symptom resolution of 11.95 hours. The company said it plans an FDA filing in the first half of 2026. Investors and analysts flagged the faster onset and shorter time to resolution versus the recently approved oral competitor as differentiators, though no head-to-head data exist. Pharvaris is also testing an extended‑release formulation for attack prevention, and executives said the program will seek to capture a share of a receptive HAE market with growing oral options.